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G R A P H I C A L A B S T R A C T
A B S T R A C T
According to the predominant theories, soluble amyloid-beta (Ab) aggregates are the principal neurotoxic agents
in Alzheimer’s disease pathology, making them a popular target for the development of therapeutics and
diagnostic markers. One of the most commonly used methods for determining the concentration of Ab is ELISA.
However, ELISA was developed for monomeric proteins and may be ill-suited for detecting aggregates. Therefore,
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we investigated the effect of aggregation on the ELISA measurement and developed a novel chemical pre-
treatment method, designed to disaggregate Ab peptides, to improve the ELISA measurement of the total Ab
concentration.
Synthetic Ab40 monomers, Ab42 oligomers and biological samples from mice and humans were subjected to a
chemical pre-treatment protocol with: triﬂuoroacetic acid (TFA), formic acid (FA) or hexaﬂuoroisopropanol
(HFIP) prior to ELISA analysis. In our study we have shown that:
 Ab oligomerization leads to epitope masking and steric hindrance and results in an underestimation of the total
Ab content with ELISA.
 Chemically pre-treating samples to disaggregate oligomers can (partially) recover the signal loss.
 This novel sample pre-treatment method could provide a more accurate ELISA measurement of the total Ab
concentration in samples with a high oligomer content.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Method details
Oligomerization of amyloid-beta (Ab) can lead to epitope masking and steric hindrance, which can
result in an underestimation of the Ab concentration in ELISA analysis (Fig. 1). We, therefore, decided
to develop a chemical pre-treatment protocol to disaggregate Ab oligomers in samples prior to
analysis. Three candidate chemicals with disaggregation properties, namely triﬂuoroacetic acid (TFA)
[1], hexaﬂuoroisopropanol (HFIP) [2] and formic acid (FA) [3] were selected from literature and
applied to various samples to evaluate efﬁcacy of the protocol and to identify the most promising
option for future research. First, the pre-treatment protocol was tested with synthetic Ab monomer
solutions to assess any unwanted effects. Next, we progressed to solutions of aggregated synthetic Ab
to determine the efﬁciency of the various treatments. Finally, we examined the compatibility of the
protocol with biological samples, i.e., brain extract of the APP23 mouse model for AD and
cerebrospinal ﬂuid from human AD patients and control individuals.
Fig. 1. Illustration of antibody binding to Ab oligomers in ELISA measurement (A). Enlarged representation of the Ab monomer
within the Ab oligomer (B). Close up of antibody binding illustrating steric hindrance and epitope masking principles (C).
Abbreviations: HRP, horseradish peroxidase.
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Synthetic Ab stock solutions
Monomeric Ab stock solutions were prepared from the human Ab1-40 standard provided with the
Human Amyloid b (1-x) Assay kit (IBL International). In order to obtain structurally homologous and
unaggregated peptides for consistent and reproducible aggregation, synthetic Ab1-42 (AnaSpec) was
processed and aliquoted in accordance with the protocol described by Stine et al. in 2003. The aliquots
were stored at 80 C until use.
Preparation of stock solutions of synthetic Ab oligomers [4]:
 Resuspend Ab1-42 aliquots to 5 mM in anhydrous dimethyl sulfoxide (DMSO).
 Sonicate for 10 min in bath sonicator.
 Dilute to 100 mM with ice-cold PBS + 0.05% sodium dodecyl sulfate (SDS).
 Allow aggregation for 24 h at 4 C.
 Dilute to 50 mg/ml and incubated at 4 C for 2 weeks to allow higher-order aggregation.
Stock solution concentrations were all determined based on the initial Ab monomer concentration.
Mouse brain protein extracts
Protein extracts were obtained from brain tissue of 18-month-old wild-type (WT) and
heterozygous APP23 mice. All mouse brains were collected with the approval of the ethical
committee for animal testing at the university of Antwerp (case number: 2013-61). Hemi-forebrains
were stored at 80 C. By using two extraction buffers in combination with varying degrees of
mechanical tissue dissociation, two protein fractions were obtained (protocol adapted from [5]).
Procedure
 Thaw hemi-forebrains on ice.
 Add 500 ml of ice-cold TNT-buffer [50 mM Tris-base (Thermo Fisher Scientiﬁc), 150 mM NaCl, 0.1%
Triton X-100, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 2 mM 1,10-phenanthroline monohydrate
(Merck Millipore), 1 protease inhibitor cocktail (Sigma–Aldrich), pH 7.40].
 Dissociate tissue with a 1-ml syringe (three aspirations without a needle and ﬁve aspirations with a
20-gauge needle).
 Dissociated further by pipetting up and down 8–10 times with a 1-ml pipette.
 Centrifuge at 18,000  g for 90 min at 4 C.
 Collect the supernatant and centrifuge a second time at 18,000  g for 90 min at 4 C.
 Collect the supernatant of this second centrifugation step and store at 20 C. This supernatant
contains the fraction of soluble proteins (SP).
 Resuspend the pellet of the ﬁrst centrifugation step in 750 ml RIPA-buffer [50 mM Tris-base (Thermo
Fisher Scientiﬁc),150 mM NaCl, 0.5% Triton X-100,1 mM ethylenediaminetetraacetic acid, 3% SDS,1%
deoxycholate, 1 mM PMSF, 2 mM 1,10-phenanthroline monohydrate (Merck Millipore), 1 protease
inhibitor cocktail (Sigma–Aldrich), pH 7.40].
 Vigorously dissociate 20 times with a 1-ml pipette.
 Vortex 20 s.
 Placed on an overhead shaker (Heidolph) for 15 min at 4 C.
 Centrifuge at 18,000  g for 90 min at 4 C.
 Collect supernatant and centrifuge a second time at 18,000  g for 90 min at 4 C.
 Collect the supernatant and store at 20 C. This supernatant contains the fraction of membrane-
bound proteins.
In this particular optimization study, only the SP fraction was used.
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Human CSF samples
Twelve CSF samples from pathologically conﬁrmed AD patients and thirteen control samples with
a similar age- and gender-proﬁle were selected from the Biobank facilities of the Institute Born-Bunge
(Antwerp, Belgium). Unlike the AD patient samples, control samples were not autopsy conﬁrmed.
However, they did not present with central nervous system pathology after neurological work-up and
neuropsychological examination revealed no cognitive deﬁcits at the time of CSF sampling. Samples
were collected during the clinical work-up of patients in compliance with the Helsinki declaration and
with the approval of the ethics committees of the ZNA hospitals and the University of Antwerp. All
samples were stored at 80 C. Three control samples and one AD patient sample had undergone one
freeze/thaw cycle prior to analysis. All other samples had never been thawed before. See
Supplementary materials for a detailed overview of the study population.
Sample pre-treatment protocol
 Dry samples in a SavantTM SpeedVacTM concentrator (Thermo Fisher Scientiﬁc).
 Reconstitute in phosphate-buffered saline (PBS), TFA, HFIP or FA.
 Place samples in a sonication bath for 15 min.
 Remove TFA and HFIP by drying under a constant stream of nitrogen gas.
or
 Remove FA and PBS by a second run in the concentrator.
 Reconstitute the samples in ultrapure water, PBS or 1%NH4OH just prior to analysis.
The samples were also diluted sequentially with each reconstitution step to obtain concentrations
within the measurement range of the applied analytical method.
Additional tips:
 To facilitate reconstitution, highly concentrated samples should be diluted a ﬁrst time prior to
starting the protocol and the ﬁrst drying step.
 The volume for reconstitution should preferably exceed the volume of the sample before drying.
Smaller volumes should be avoided at all costs.
 Drying times can vary for different volumes and buffers and should be optimized. While samples
should be dried completely, excessive drying should be avoided.
ELISA measurements
ELISA measurements were carried out using the Human Amyloid b (1-x) Assay kit (IBL
International) in accordance with the manufacturer’s instructions. This kit has a detection range
between 7.81 and 500 pg/ml and can detect Ab forms of various lengths, ranging from 28 to 42 amino
acids, provided they show no N-terminal modiﬁcation. Cross reactivity with N-terminally modiﬁed Ab
amounts to 0.1%.
SDS-PAGE and Western blotting
Aggregation and disaggregation of standard solutions were evaluated using SDS-PAGE and Western
blotting. NuPAGE1 LDS sample buffer was added to the samples prior to gel loading. Denaturing, non-
reducing SDS-PAGE was performed with the Xcell SureLock mini-cell system (Life Technologies)
according to the standard protocol using pre-cast NuPage1 4–12% bis-Tris gels and NuPAGE1MES SDS
running buffer (Life Technologies). After electrophoresis, the proteins were blotted to Immobilon1-
PSQ membrane (Millipore) in the XCell IITM Blot Module (Life Technologies) using the standard
manufacturer’s protocol. Ab was labeled overnight at 4 C with 6E10-antibody (Covance) and
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horseradish peroxidase-conjugated anti-mouse antibody (Dako). The blocking buffer consisted of
Tween120-Tris buffered saline [10 mM Tris-base (Thermo Fisher Scientiﬁc), 200 mM NaCl (Merck
Milipore), 0.1% Tween20 (Bio-Rad Laboratories), pH 7.40] and 5% bovine serum albumin 98% grade
(Merck Milipore). Protein bands were visualized using the SuperSignalTM West Femto chemilumi-
nescent substrate (Thermo Fisher Scientiﬁc). Blots were imaged and analysed with the G:Box imager
equipped with Genesnap and Genetools software (Syngene).
Statistical analysis
All statistical tests were performed with the level of probability set at 95% using IBM SPSS statistics
22.0.0 software (IBM). Low inter-sample variability was expected in analyses of standard stock
solutions. Extreme outliers (values exceed more than three times the interquartile range) were
suspected to be the result of procedural aberrations and therefore excluded from the dataset. The
various treatment groups of the standard solution were compared using a one-way ANOVA with a
Bonferroni post-hoc test. The genotype groups of the brain extract samples were compared for each
treatment with the independent-samples Mann–Whitney U test. A paired statistical analysis, using
the related samples Wilcoxon signed rank test, was performed to compare the measurements of
untreated brain extracts to the measurement of the sample after a given treatment. The results of the
analysis of the human CSF samples were analysed by a two-way repeated measures ANOVA with a
Bonferonni post hoc test for the comparison between treatment groups.
Method validation using monomeric Ab stock solution
Initially, we investigated whether the chemical treatments had any unwanted effects on the ELISA
measurement of Ab by subjecting our standard solution of synthetic Ab 1-40 monomers (0.1 ng/ml) to
the various treatments. ELISA results indicated signiﬁcant, unwanted effects in some treatment groups
(F4,37 = 42.813; p < 0.0001; Fig. 2). Post-hoc Bonferroni tests between the individual groups showed
there was no signiﬁcant difference between measurements of untreated standard and TFA-treated
(p = 0.884) or FA-treated (p = 0.231) standard. On average, these three groups showed minimal
deviation (<10%) from the theoretical standard concentration, demonstrating no adverse effect of
Fig. 2. Results of ELISA measurements of Ab40monomer standard solution. Comparison of means (SD) between the untreated
(n = 7), PBS (n = 8), TFA (n = 8), HFIP (n = 8) and FA group (n = 7). Asterisks represent signiﬁcant differences between the untreated
group and treatment groups (post-hoc Bonferroni test; ***p < 0.001). The dashed line represents the standard’s theoretical
concentration. Abbreviations: FA, formic acid; HFIP, hexaﬂuoroisopropanol; PBS, phosphate-buffered saline; TFA, triﬂuoroacetic
acid.
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these sample pre-treatments on sample recovery. The control group, treated with PBS, and the
HFIP-treated group did appear to experience a signiﬁcant reduction in signal due to the procedure,
when compared to the untreated group (both p < 0.0001; Fig. 2). The fact that the PBS control group
was affected and that there was no real difference between the PBS group and HFIP group (p = 1.000),
seems to indicate that the observed effect is caused by the process of drying and reconstituting the
samples, rather than by the chemical itself.
Method validation using oligomeric Ab stock solution
Next, we investigated the effects of the various chemical treatments on a standard solution of
synthetic Ab1-42 oligomers, which were serially diluted to a concentration of approximately
0.350 ng/ml (concentration based on the initial Ab monomer concentration at the start of the
aggregation procedure) prior to analysis. ELISA results showed no signiﬁcant difference between the
untreated and the PBS-treated standard (p = 1.000; Fig. 3). However, the measured Ab levels for both
groups averaged 10–15% of the theoretical standard concentration, demonstrating the impact of
oligomers on ELISA measurements. While the FA treatment did result in a slight increase in the Ab
signal, the signal did not differ signiﬁcantly from the untreated group (p = 0.715) and still only reached
about 25% of the theoretical value. Treatment with TFA or HFIP did yield a signiﬁcant increase in signal
compared to the untreated group (both p < 0.0001). Despite the fact that HFIP treatment showed a
decrease in signal in the tests with the monomer standard, the mean value of the HFIP-treated group
actually came close to 65% of the theoretical concentration. The TFA group even exceeded the
theoretical value. However, given that this theoretical value was calculated based on the serial dilution
of the original stock solution and that ELISA tests are not 100% accurate, some deviation can be
expected. Western blotting conﬁrmed disaggregation by all three treatments, although some low
n-oligomers could still be observed (Fig. 4). It is unclear, however, whether these oligomers were
unaffected by the treatment, re-formed during the SDS-PAGE and Western blotting procedure or a
combination of both. As the use of SDS has been associated with the induction of Ab oligomerization
[6], it cannot be excluded that the observed low n-oligomers are an artefact caused by the SDS in the
procedure. The TFA treatment did show the least amount of these low n-oligomers and the ELISA
Fig. 3. Results of ELISA measurements of Ab42 oligomer standard solution. Comparison of means (SD) between the untreated
(n = 17), PBS (n = 16), TFA (n = 7), HFIP (n = 10) and FA group (n = 8). Asterisks represent signiﬁcant differences between the
untreated group and treatment groups (post-hoc Bonferroni test; ***p < 0.001). The dashed line represents the standard’s
theoretical concentration. Abbreviations: FA, formic acid; HFIP, hexaﬂuoroisopropanol; PBS, phosphate-buffered saline; TFA,
triﬂuoroacetic acid.
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results seem to indicate a (near) complete disaggregation after TFA. TFA would thus appear to be the
most efﬁcient treatment in these experiments.
Method validation using biological samples
Finally, we explored the effect of sample pre-treatment on biological samples, i.e., protein extracts
from brain tissue of APP23 mice (Fig. 5) and human CSF samples (Fig. 6). Since the FA treatment failed
to produce a signiﬁcant effect in the ELISA measurements of the oligomer standard, it was not included
in these further experiments. Due to the more complex matrix of the brain extracts and the fact that
we previously diagnosed a possible problem with reconstitution after HFIP treatment, we did include
three reconstitution solutions for comparison: ultrapure water, PBS and a 1% NH4OH solution. Since
WT mice do not express human Ab, all treatment groups showed a clear difference in Ab
measurements between WT and heterozygous mice (p < 0.005). The more important question is of
course whether the pre-treatments resulted in an increase of the ELISA signal in samples of
heterozygous mice similar to the increase observed with the oligomer standard. When comparing the
results of the heterozygote samples with and without treatment, we found no signiﬁcant differences
between the untreated samples and the PBS-treated (p = 0.917), the TFA–PBS-treated (p = 0.249) and
the HFIP–ultrapure water-treated samples (p = 0.600). The TFA–ultrapure water treatment group, the
TFA–1%NH4OH group, the HFIP–PBS group and the HFIP–1%NH4OH group all exhibited a signiﬁcant
increase in signal (p < 0.05). Ideally, the WT samples are unaffected by the treatment. In reality,
however, the signal of WT samples was lowered signiﬁcantly in the TFA–PBS, the HFIP–ultrapure
Fig. 4. Western blot results after SDS-PAGE of the Ab42 oligomer standard solution without treatment and after treatment with
FA, TFA, or HFIP. Abbreviations: FA, formic acid; HFIP, hexaﬂuoroisopropanol; TFA, triﬂuoroacetic acid. (Lanes were cropped
from one blot, for the full image, see Supplementary materials).
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water and the HFIP–PBS group (p < 0.05). On the other hand, in the PBS-treated group a slight increase
was observed (p = 0.046). The other treatment groups did not display a signiﬁcant difference between
untreated and treated WT samples. As 1%NH4OH appeared to be the most efﬁcient reconstitution
buffer for both TFA and HFIP-treated brain extracts, we selected this reconstitution buffer for the
Fig. 5. ELISA results of brain extracts. Comparison of heterozygote (black squares) and wild-type (open circle) samples without
treatment and after PBS, TFA–MQ, TFA–PBS, TFA–1%NH4OH, HFIP–MQ, HFIP–PBS or HFIP–1%NH4OH treatment. Horizontal lines
represent the mean for each genotype per treatment. Abbreviations: FA, formic acid; HFIP, hexaﬂuoroisopropanol; MQ,
ultrapure water; PBS, phosphate-buffered saline; TFA, triﬂuoroacetic acid.
Fig. 6. Elisa results of human CSF samples. Comparison of means (SD) between AD patient (n = 12) and control (n = 13) samples
without treatment and after treatment with TFA or HFIP. All treated samples were reconstituted in 1%NH4OH. Asterisks
represent signiﬁcant differences between the untreated group and treatment groups (post-hoc Bonferroni test; ***p < 0.001).
Abbreviations: AD, Alzheimer’s disease; HFIP, hexaﬂuoroisopropanol; TFA, triﬂuoroacetic acid.
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experiments with human CSF. Contrary to the results from the brain extracts, treatment of the CSF
samples resulted in a decrease in the ELISA signal for both TFA-treated and HFIP-treated samples when
compared to the untreated samples (p < 0.001, Fig. 6). No signiﬁcant difference could be observed
between the control samples and the AD samples (p = 0.217) and the effect of the various treatments
was also similar for both groups (p = 0.230). Treatment of the brain extract samples resulted in an
increased scatter of the data. Whether this simply reﬂects the biological variability in Ab aggregation
or is an issue of consistency/reproducibility of the treatment procedure, remains to be investigated.
The human CSF samples, however, did not show an increased scatter after treatment. Before applying
the protocol, it should be extensively validated for reproducibility and proper controls should be
included in any experiment.
Additional information
Background
Ever since its ﬁrst description by Dr. Alois Alzheimer in 1906, Alzheimer’s disease (AD) has been
associated with two distinctive histopathological lesions: amyloid plaques of aggregated Ab and
neuroﬁbrillary tangles of hyperphosphorylated tau. Subsequent Alzheimer research has, therefore,
mainly focused on elucidating the relationship between these proteins and the observed symptomatol-
ogy in the hope of identifying diagnostic markers and possible therapeutic targets. This research
uncovered signiﬁcant genetic and biochemical evidence (for reviews [7–10]), which contributed to the
development of the amyloid cascade hypothesis. According to this hypothesis, the Ab peptide plays a
central role in AD pathology [11], rendering Ab the focal point of many research endeavors. It became
apparent, however, that the ﬁbrillar Ab in plaques correlated poorly with the cognitive impairment
observed in AD patients [12,13]. Soluble, non-ﬁbrillar Ab aggregates, however, correlate strongly with
disease severity and synaptic alterations [14–16]. These discoveries led to a more reﬁned version of the
amyloid cascade hypothesis in which soluble Ab aggregates are cast as the principal neurotoxic agent in
AD pathology [17]. To this day, this hypothesis is still the most widely accepted theory and Ab remains a
popular target for the development of therapeutics and diagnostic markers. In fact, several imaging and
biochemical methods have already been developed to determine Ab levels for diagnostic purposes
[18–23]. One of the most commonly used tools for the determination of Ab concentrations is an
immunoassay. During recent revisions of the diagnostic criteria for AD, ELISA-based analyses were even
included as a possible supportive measure in the diagnosis of AD [24,25]. ELISA, however, was designed
for the detection of monomeric proteins. Unfortunately, Ab has a tendency to aggregate and, as
mentioned earlier, these aggregates are considered to be crucial to the pathology. The capacity of
immunoassays to properly detect these aggregates and accurately determine the total Ab concentration
has been called into question [26,27]. ELISA measurements are based on the principle that each target
protein will bind a single enzyme-conjugated antibody, resulting in a measurable signal that is
proportional to the quantity of protein in the sample. Upon aggregation, however, the hydrophobic
C-terminus ofAb getsinternalizedinthe coreof theaggregate [28], givingriseto epitopemasking, i.e., the
antibody binding site becomes inaccessible for the antibody (Fig.1). In addition, given the relatively small
size of Ab (4–5 kDa) and the large size of the ELISA antibodies (150 kDa), steric hindrance could also
inhibit the binding of multiple detection antibodies in close proximity of each other (Fig. 1). Spatial
limitations might prevent some of the Ab peptides in an aggregate from binding to a detection antibody
and contributing to the measured concentration. Together, these two effects make it impossible to
determine how many antibodies, if any, a given aggregate will bind. The obtained signal will, therefore,
not accurately represent the total Ab content and lead to an underestimation of the actual concentration.
Due to these inherent problems with the traditional ELISA and the important role of soluble Ab
aggregates in AD pathology, several research groups have been developing new immunoassays to
speciﬁcally target Ab aggregates. Some of these groups have chosen to adapt the traditional ELISA by
using aggregate-speciﬁc antibodies [29–32], or by using a single monoclonal antibody for both antigen
capture and detection [29,32–37]. Others groups apply techniques like a bio-barcode assay [38], surface-
ﬂuorescence intensity distribution analysis [39] or ﬂuorescence resonance energy transfer in
combination with ﬂow cytometry [40]. With the exception of the assays using aggregate-speciﬁc
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antibodies, all these methods still rely on the binding of multiple antibodies and are vulnerable to the
effects of epitope masking and steric hindrance. The aggregate-speciﬁc assays are entirely reliant on the
selection of an appropriate conformational antibody and run the risk of merely detecting a subset of
oligomers with that speciﬁc conformation. Finally, none of these tests provides information on the total
Ab level. Therefore, instead of trying to modify immunoassays to detect whole aggregates, another
approach might be to disaggregate Ab in samples prior to analysis. After all, the ELISA technique was
designed to provide quantitative and not structural information. As this approach will result in the loss of
aggregate structures in the samples, information about the aggregate concentration and the degree of
aggregationwill be lost.Where aggregate speciﬁc tests provideinformation on aggregate concentrations,
this method measures the total concentration of Ab monomers. However, it might be possible to deduce
some information about the degree of aggregation in samples by calculating the before/after treatment
ratio.
Conclusions
Overall, our study has shown that the presence of oligomers in samples can seriously affect the
accuracy of ELISA measurements of the total Ab content. The validation experiment with the
oligomeric stock solution clearly shows a decrease in signal and the resulting underestimation of
the Ab content. In samples with a signiﬁcant oligomer content, like the oligomer stock solution and
the brain extracts, both TFA and HFIP treatment appeared capable of disaggregating oligomers and
recovering the lost signal. In samples with a low oligomer content, like the monomeric stock solution
or the CSF samples [31,35–37], the pre-treatment method did not induce an increase in signal, which is
to be expected. On the contrary, some samples actually showed a loss in signal, most likely due to
incomplete protein recovery upon reconstitution after drying. As the effect of oligomers on the
accuracy of the ELISA measurements will be negligible in samples with low oligomer content,
pre-treatment of these samples is inadvisable. The 1% NH4OH solution appeared to be the best option
for reconstitution in our experiments, but some additional optimization might be necessary
depending on the samples and analytical method used.
Acknowledgments
MethodsX thanks the reviewers of this article for taking the time to provide valuable feedback This
work was supported by a research grant of the Research Foundation-Flanders (FWO), Interuniversity
Poles of Attraction (IAP Network P7/16) of the Belgian Federal Science Policy Ofﬁce, Methusalem
excellence grant of the Flemish Government, agreement between Institute Born-Bunge and University
of Antwerp, the Medical Research Foundation Antwerp, the Thomas Riellaerts research fund, and
Neurosearch Antwerp. Debby Van Dam is a postdoctoral fellow of the FWO. We would like to thank
them. Prof. Dr. B. Marescau for his counsel and assistance in the selection of chemicals and drying
procedures. We would also like to thank Geert Van Raemdonck and Edmond Coen for the use of the
SpeedVacTM concentrator and their expert advice.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.
org/10.1016/j.mex.2015.02.011.
References
[1] S.C. Jao, K. Ma, J. Talafous, R. Orlando, M.G. Zagorski, Triﬂuoroacetic acid pretreatment reproducibly disaggregates the
amyloid beta-peptide, Amyloid 4 (1997) 240–252.
[2] W.B. Stine Jr., K.N. Dahlgren, G.A. Krafft, M.J. LaDu, In vitro characterization of conditions for amyloid-beta peptide
oligomerization and ﬁbrillogenesis, J. Biol. Chem. 278 (2003) 11612–11622.
[3] D.J. Selkoe, C.R. Abraham, M.B. Podlisny, L.K. Duffy, Isolation of low-molecular-weight proteins from amyloid plaque ﬁbers
in Alzheimer’s disease, J. Neurochem. 46 (1986) 1820–1834.
L. Janssen et al. / MethodsX 2 (2015) 112–123 121
[4] D.A. Ryan, W.C. Narrow, H.J. Federoff, W.J. Bowers, An improved method for generating consistent soluble amyloid-beta
oligomer preparations for in vitro neurotoxicity studies, J. Neurosci. Methods 190 (2010) 171–179.
[5] M.A. Sherman, S.E. Lesne, Detecting abeta*56 oligomers in brain tissues, Methods Mol. Biol. 670 (2011) 45–561.
[6] A.D. Watt, K.A. Perez, A. Rembach, N.A. Sherrat, L.W. Hung, T. Johanssen, C.A. McLean, W.M. Kok, C.A. Hutton, M. Fodero-
Tavoletti, C.L. Masters, V.L. Villemagne, K.J. Barnham, Oligomers, fact or artefact? SDS-PAGE induces dimerization of
b-amyloid in human brain samples, Acta Neuropathol. 125 (4) (2013) 549–564.
[7] D.M. Walsh, D.J. Selkoe, A beta oligomers – a decade of discovery, J. Neurochem. 101 (2007) 1172–1184.
[8] A.L. Lublin, S. Gandy, Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer’s Disease, Mt. Sinai J. Med. 77
(2010) 43–49.
[9] A. Goate, J. Hardy, Twenty years of Alzheimer’s disease-causing mutations, J. Neurochem. 120 (Suppl 1) (2012) 3–8.
[10] M.E. Larson, S.E. Lesne, Soluble Abeta oligomer production and toxicity, J. Neurochem. 120 (Suppl 1) (2012) 125–139.
[11] J.A. Hardy, G.A. Higgins, Alzheimer’s disease: the amyloid cascade hypothesis, Science 256 (1992) 184–185.
[12] R.D. Terry, E.Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill,L.A. Hansen,R. Katzman, Physical basis of cognitive alterations
in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment, Ann. Neurol. 30 (1991) 572–580.
[13] D.W. Dickson, H.A. Crystal, C. Bevona, W. Honer, I. Vincent, P. Davies, Correlations of synaptic and pathological markers
with cognition of the elderly, Neurobiol. Aging 16 (1995) 285–298 discussion 298–304.
[14] C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, C.L. Masters, Soluble pool of Abeta
amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease, Ann. Neurol. 46 (1999) 860–866.
[15] L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J.H. Kurth, R.E. Rydel, J. Rogers, Soluble amyloid beta
peptide concentration as a predictor of synaptic change in Alzheimer’s disease, Am. J. Pathol. 155 (1999) 853–862.
[16] J. Wang, D.W. Dickson, J.Q. Trojanowski, V.M. Lee, The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s
disease from normal and pathologic aging, Exp. Neurol. 158 (1999) 328–337.
[17] J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics,
Science 297 (2002) 353–356.
[18] C.R. Jack Jr., D.W. Dickson, J.E. Parisi, Y.C. Xu, R.H. Cha, P.C. O’Brien, S.D. Edland, G.E. Smith, B.F. Boeve, E.G. Tangalos, E.
Kokmen, R.C. Petersen, M.R.I. antemortem ﬁndings correlate with hippocampal neuropathology in typical aging and
dementia, Neurology 58 (2002) 750–757.
[19] D.H. Silverman, S.S. Gambhir, H.W. Huang, J. Schwimmer, S. Kim, G.W. Small, J. Chodosh, J. Czernin, M.E. Phelps, Evaluating
early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and
beneﬁts, J. Nucl. Med. 43 (2002) 253–266.
[20] F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider, P.P. De Deyn, C. Bancher, P. Cras, J. Wiltfang,
P.D. Mehta, K. Iqbal, H. Pottel, E. Vanmechelen, H. Vanderstichele, Improved discrimination of AD patients using beta-
amyloid(1-42) and tau levels in CSF, Neurology 52 (1999) 1555–1562.
[21] O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, L. Minthon, Association between CSF biomarkers and incipient
Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol. 5 (2006) 228–234.
[22] W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt, M. Bergstrom, I. Savitcheva, G.F. Huang, S. Estrada, B.
Ausen, M.L. Debnath, J. Barletta, J.C. Price, J. Sandell, B.J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C.A. Mathis, B. Langstrom,
Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B, Ann. Neurol. 55 (2004) 306–319.
[23] K. Shoghi-Jadid, G.W. Small, E.D. Agdeppa, V. Kepe, L.M. Ercoli, P. Siddarth, S. Read, N. Satyamurthy, A. Petric, S.C. Huang, J.R.
Barrio, Localization of neuroﬁbrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer
disease, Am. J. Geriatr. Psychiatry 10 (2002) 24–35.
[24] B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G.
Jicha, K. Meguro, J. O’Brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P.J. Visser, P. Scheltens, Research criteria for
the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria, Lancet Neurol. 6 (2007) 734–746.
[25] G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, W.E. Klunk, W.J. Koroshetz, J.J. Manly, R.
Mayeux, R.C. Mohs, J.C. Morris, M.N. Rossor, P. Scheltens, M.C. Carrillo, B. Thies, S. Weintraub, C.H. Phelps, The diagnosis of
dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement. 7 (2011) 263–269.
[26] C. Stenh, H. Englund, A. Lord, A.S. Johansson, C.G. Almeida, P. Gellerfors, P. Greengard, G.K. Gouras, L. Lannfelt, L.N. Nilsson,
Amyloid-beta oligomers are inefﬁciently measured by enzyme-linked immunosorbent assay, Ann. Neurol. 58 (2005)
147–150.
[27] H. Englund, M. Degerman Gunnarsson, R.M. Brundin, M. Hedlund, L. Kilander, L. Lannfelt, F.E. Pettersson, Oligomerization
partially explains the lowering of Abeta42 in Alzheimer’s disease cerebrospinal ﬂuid, Neurodegener. Dis. 6 (2009) 139–147.
[28] A.E. Roher, J. Baudry, M.O. Chaney, Y.M. Kuo, W.B. Stine, M.R. Emmerling, Oligomerizaiton and ﬁbril asssembly of the
amyloid-beta protein, Biochim. Biophys. Acta 1502 (2000) 31–43.
[29] H. Englund, D. Sehlin, A.S. Johansson, L.N. Nilsson, P. Gellerfors, S. Paulie, L. Lannfelt, F.E. Pettersson, Sensitive ELISA
detection of amyloid-beta protoﬁbrils in biological samples, J. Neurochem. 103 (2007) 334–345.
[30] Z. van Helmond, K. Heesom, S. Love, Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on
human brain tissue homogenates, J. Neurosci. Methods 176 (2009) 206–212.
[31] A.Z. Herskovits, J.J. Locascio, E.R. Peskind, G. Li, B.T. Hyman, A Luminex assay detects amyloid beta oligomers in Alzheimer’s
disease cerebrospinal ﬂuid, PLoS One 8 (2013) e67898.
[32] T. Yang, S. Hong, T. O’Malley, R.A. Sperling, D.M. Walsh, D.J. Selkoe, New ELISAs with high speciﬁcity for soluble oligomers of
amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF, Alzheimers Dement. 9 (2013) 99–112.
[33] A. Lord, A. Gumucio, H. Englund, D. Sehlin, V.S. Sundquist, L. Soderberg, C. Moller, P. Gellerfors, L. Lannfelt, F.E. Pettersson, L.
N. Nilsson, An amyloid-beta protoﬁbril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s
disease, Neurobiol. Dis. 36 (2009) 425–434.
[34] H. Fukumoto, T. Tokuda, T. Kasai, N. Ishigami, H. Hidaka, M. Kondo, D. Allsop, M. Nakagawa, High-molecular-weight beta-
amyloid oligomers are elevated in cerebrospinal ﬂuid of Alzheimer patients, FASEB J. 24 (2010) 2716–2726.
122 L. Janssen et al. / MethodsX 2 (2015) 112–123
[35] W. Xia, T. Yang, G. Shankar, I.M. Smith, Y. Shen, D.M. Walsh, D.J. Selkoe, A speciﬁc enzyme-linked immunosorbent assay for
measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease, Arch.
Neurol. 66 (2009) 190–199.
[36] M. Holtta, O. Hansson, U. Andreasson, J. Hertze, L. Minthon, K. Nagga, N. Andreasen, H. Zetterberg, K. Blennow, Evaluating
amyloid-beta oligomers in cerebrospinal ﬂuid as a biomarker for Alzheimer’s disease, PLoS One 8 (2013) e66381.
[37] M.J. Savage, J. Kalinina, A. Wolfe, K. Tugusheva, R. Korn, T. Cash-Mason, J.W. Maxwell, N.G. Hatcher, S.J. Haugabook, G. Wu, B.
J. Howell, J.J. Renger, P.J. Shughrue, A. McCampbell, A sensitive abeta oligomer assay discriminates Alzheimer’s and aged
control cerebrospinal ﬂuid, J. Neurosci. 34 (2014) 2884–2897.
[38] D.G. Georganopoulou, L. Chang, J.M. Nam, C.S. Thaxton, E.J. Mufson, W.L. Klein, C.A. Mirkin, Nanoparticle-based detection in
cerebral spinal ﬂuid of a soluble pathogenic biomarker for Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A. 102 (2005)
2273–2276.
[39] L. Wang-Dietrich, S.A. Funke, K. Kühbach, K. Wang, A. Besmehn, S. Willbold, Y. Cinar, O. Bannach, E. Birkmann, D. Willbold,
The amyloid-beta oligomer count in cerebrospinal ﬂuid is a biomarker for Alzheimer’s disease, J. Alzheimers Dis. 34 (2013)
985–994.
[40] A.N. Santos, S. Torkler, D. Nowak, C. Schlittig, M. Goerdes, T. Lauber, L. Trischmann, M. Schaupp, M. Penz, F.W. Tiller, G.
Bohm, Detection of amyloid-beta oligomers in human cerebrospinal ﬂuid by ﬂow cytometry and ﬂuorescence resonance
energy transfer, J. Alzheimers Dis. 11 (2007) 117–125.
L. Janssen et al. / MethodsX 2 (2015) 112–123 123
